RS 09

Product Name:RS 09

CAS No:1449566-36-2

Purity:95%

Molar Mass:691.78

Chemical Formula:C31H49N9O9

Storage:Store at -20 degrees Celsius

Sequence:APPHALS

Target:TLR4 agonist

Application:

RS 09 is a small molecule agonist of Toll-like receptor 4 (TLR4), a key receptor in the innate immune system that recognizes pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). TLR4 activation triggers a pro-inflammatory response, making RS 09 useful in studying immune responses, inflammation, and related signaling pathways. It is particularly valuable for research into inflammatory diseases, infections, and cancer immunotherapy, where modulating TLR4 activity can influence immune activation. RS 09 is employed in exploring therapeutic strategies for conditions involving immune dysregulation and to understand TLR4’s role in immune system function.

Current Research:

RS 09 (CAS: 1449566-36-2) is a synthetic peptide that functions as a Toll-like receptor 4 (TLR4) agonist. It mimics lipopolysaccharide (LPS) and serves as an adjuvant to enhance immune responses.

Mechanism of Action

By activating TLR4, RS 09 promotes the nuclear translocation of NF-κB in RAW264.7 macrophages, leading to the secretion of inflammatory cytokines. This activation stimulates the innate immune system, enhancing the body's defense mechanisms.

Adjuvant Properties

In vivo studies have demonstrated that RS 09 can enhance antigen-specific antibody production. For instance, when administered with X-15-KLH in mice, RS 09 increased serum concentrations of X-15 specific antibodies, indicating its potential as a vaccine adjuvant.

Applications in Research

RS 09 is utilized in immunological research to study TLR4-mediated signaling pathways and to develop novel vaccine adjuvants. Its ability to modulate immune responses makes it a valuable tool for investigating the mechanisms of innate immunity and for enhancing the efficacy of vaccines.

Conclusion

As a TLR4 agonist, RS 09 plays a significant role in modulating immune responses, offering potential applications in vaccine development and immunotherapy research.

Reference:

Shanmugam, A., Rajoria, S., George, A. L., Mittelman, A., Suriano, R., & Tiwari, R. K. (2012). Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants. PloS one, 7(2), e30839.